CONMED Corporation (NASDAQ:CNMD) updated its FY17 earnings guidance on Thursday. The company provided EPS guidance of $1.85-1.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.87.

A number of equities analysts recently issued reports on the stock. BidaskClub downgraded shares of CONMED Corporation from a sell rating to a strong sell rating in a research note on Saturday, August 5th. Zacks Investment Research raised shares of CONMED Corporation from a sell rating to a hold rating in a research note on Tuesday. TheStreet raised shares of CONMED Corporation from a c+ rating to a b- rating in a research note on Thursday, August 3rd. Needham & Company LLC raised their target price on shares of CONMED Corporation from $54.00 to $57.00 and gave the company a buy rating in a research note on Thursday, July 27th. Finally, KeyCorp reaffirmed a hold rating on shares of CONMED Corporation in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $52.50.

CONMED Corporation (NASDAQ:CNMD) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.41 by $0.01. CONMED Corporation had a net margin of 2.02% and a return on equity of 8.38%. The business had revenue of $190.10 million during the quarter, compared to analyst estimates of $187.13 million. During the same quarter in the previous year, the business posted $0.41 EPS. The company’s quarterly revenue was up 2.9% compared to the same quarter last year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 5th. Stockholders of record on Friday, September 15th were issued a $0.20 dividend. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.53%. CONMED Corporation’s dividend payout ratio is currently 142.86%.

In other news, Director Jo Ann Golden sold 3,000 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the director now owns 19,782 shares in the company, valued at approximately $989,100. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CONMED Corporation (CNMD) Issues FY17 Earnings Guidance” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/11/02/conmed-corporation-cnmd-issues-fy17-earnings-guidance.html.

CONMED Corporation Company Profile

CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

Earnings History and Estimates for CONMED Corporation (NASDAQ:CNMD)

Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.